Table 3.
Multivariate analysis of 3-year clinical outcomes.
| 3-Year All-Cause Mortality | 3-Year MACE | |||
|---|---|---|---|---|
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
| Model 1 * | ||||
| Low L1 SMI | 4.34 (2.45–7.69) | <0.001 | 3.82 (2.54–5.74) | <0.001 |
| Model 2 † | ||||
| Low L1 SMI | 3.74 (1.89–7.41) | <0.001 | 4.51 (2.76–7.38) | <0.001 |
| Model 3 ‡ | ||||
| Low L1 SMI | 3.69 (1.81–7.52) | <0.001 | 3.77 (2.27–6.27) | <0.001 |
| Model 4 § | ||||
| Low L1 SMI | 4.07 (1.95–8.45) | <0.001 | 3.76 (2.27–6.23) | <0.001 |
| Model 5 || (PSM analysis) | ||||
| Low L1 SMI | 2.68 (1.23–5.83) | 0.013 | 2.80 (1.56–5.03) | 0.001 |
* Univariate analysis; † adjusted for age, sex, and body mass index; ‡ further adjusted for left ventricular ejection fraction <50%, creatinine clearance <60 mL/min, Total cholesterol >5.17 mmol/L (>200 mg/dL), clopidogrel at discharge, statins at discharge, and average diameter of inserted stents; § further adjusted for clinical presentation as myocardial infarction, hypertension, diabetes, previous malignancy, multivessel disease, and implantation of second generation drug-eluting stents. || propensity score-matched analysis; further adjusted for dyslipidemia, number of treated lesions and treated vessels, number of implanted stents, and total stent length. CI = confidence interval; HR = hazard ratio; L1 = first lumbar vertebra; MACE = major adverse cardiovascular event; PSM = propensity score-matched; SMI = skeletal muscle index.